Low-dose daratumumab therapy for antibody-mediated rejection in kidney transplantation: a single-center experience (TTS 2026) - Sep 17, 2026 - Abstract #P4.805; Pres time: Sep 22, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P4; "Standard-of-care therapies, such as corticosteroids, intravenous immunoglobulin, plasma exchange, or rituximab, provide inconsistent responses. In this preliminary single-center experience, low-dose daratumumab was associated with marked DSA reduction and improved histologic activity at 6-month follow-up, with a favorable short-term safety profile. A high baseline DSA burden may identify patients less likely to achieve complete response with limited dosing. These findings support prospective studies to refine dosing strategies and evaluate durability of response and long-term allograft outcomes."
Clinical • Antibody-mediated Rejection • Infectious Disease • Transplantation
|
|
Gabriele Mortari1; Maurizio Bruschi2; Antonella Trivelli1; Fabrizio Ginevri1; Arcangelo Nocera1; Patrizia Comoli3; Sonia Spinelli2; Enrico Eugenio Verrina1; Alberto Magnasco1
|